NAD+ research: from redox chemistry to the human precursor trials

In plain English

NAD+ is a helper molecule every cell uses to release energy from food, and a fuel source for repair-and-maintenance enzymes. As we age, cells hold less of it. Researchers have tested whether feeding the body precursors — building blocks called NMN and NR that it turns into NAD+ — can push levels back up. The clear result: oral NMN and NR reliably raise NAD+ in the blood, and some trials saw better muscle insulin response and exercise capacity. The unsettled part: nobody has yet shown that raising NAD+ this way prevents disease or extends healthy lifespan in people. This page lays out both halves with citations.

Mechanism: One Coenzyme, Two Jobs

NAD+ does two distinct things. First, it is a redox shuttle: it accepts electrons to become NADH during catabolism and donates them in the mitochondrial electron transport chain to drive ATP synthesis ^[5]. Second, it is a consumed substrate — sirtuins, PARP1 and CD38 cleave it as part of their reactions, so signaling literally spends the NAD+ pool ^[5][13].

PARP1 (poly(ADP-ribose) polymerase 1) consumes large amounts of NAD+ when it responds to DNA damage; one review frames NAD+ as the limiting substrate that couples PARP1-driven DNA repair to cellular energy depletion and, when PARP1 over-activates, to cell death relevant to ischemia and inflammation ^[13]. CD38 is the third major consumer and the one most clearly tied to age ^[2]. The salvage pathway replenishes the pool: nicotinamide is converted to NMN by NAMPT (the rate-limiting step), and NMN to NAD+ by NMNAT ^[5]. NR enters one step upstream, converted to NMN by NRK kinases — a route independent of the Preiss-Handler pathway ^[5].

What Human Supplement Trials Have Reported

The most replicated human result is that oral precursors raise blood NAD+ in proportion to dose. NR at 100/300/1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%/51%/142%, without elevating LDL cholesterol or disrupting one-carbon metabolism ^[4]. A multicenter, double-blind NMN trial (300/600/900 mg/day, 60 days) raised blood NAD+ at days 30 and 60 across all groups versus placebo (p≤0.001), improved six-minute walking distance, and saw a biological-age measure that did not increase; 600 mg/day was identified as optimal, with no safety issues at any dose ^[3].

Functional endpoints are where the record is most encouraging and most specific. In prediabetic, postmenopausal women, NMN 250 mg/day for 10 weeks increased muscle insulin sensitivity and remodeled insulin signaling, with no change in body composition or HbA1c ^[1]. In amateur runners, NMN 250 mg/day for 12 weeks raised ventilatory thresholds during incremental treadmill testing, interpreted as improved skeletal-muscle oxygen utilization ^[7]. A longer NMN study in older adults (100–500 mg/day, 24 weeks) raised blood NAD+ dose-dependently and improved lower-limb function at the higher doses ^[6].

The Preclinical Foundation

The mouse literature is where the largest effects appear. Long-term oral NMN (100–300 mg/kg/day for 12 months) suppressed age-associated weight gain, enhanced energy metabolism, and improved insulin sensitivity, eye function and bone density, with no observed toxicity ^[8]. NMN also reversed the diabetes-like pathophysiology of high-fat-diet and aged mice: high-fat feeding compromised NAMPT-driven NAD+ biosynthesis, and NMN (500 mg/kg) restored NAD+ in liver and skeletal muscle, improved glucose tolerance, and enhanced hepatic insulin sensitivity partly through SIRT1 ^[10].

NAD+ also sits at the center of inflammatory signaling. In mouse macrophages, intracellular NAD+ depletion (via the NAMPT inhibitor FK866) primed NLRP3 inflammasome assembly and caspase-1 activation — an effect reversed by restoring NAD+ with NMN ^[11]. Separately, lipopolysaccharide-activated macrophages generated mitochondrial-ROS DNA damage that activated PARP and consumed NAD+, making the cells dependent on NAMPT-driven salvage to sustain their metabolism ^[14]. A 2024 study added that de novo serine synthesis limits macrophage NAD+ and NAD+-dependent SIRT activity to sustain IL-1β production ^[15].

The Muscle and Metabolic Thread

Across the human trials, the most consistent functional signal sits in muscle and metabolism. The Yoshino 2021 result is the anchor: a hyperinsulinemic-euglycemic clamp — the reference method for measuring insulin sensitivity — showed NMN 250 mg/day improved muscle insulin sensitivity and remodeled insulin signaling in prediabetic, postmenopausal women ^[1]. The Liao 2021 runners trial added an exercise-physiology readout, with NMN raising ventilatory thresholds during incremental treadmill testing ^[7], and the Kim 2022 older-adult study reported improved lower-limb function alongside dose-dependent blood-NAD+ elevation ^[6].

The mouse work points the same direction with larger effects: NMN restored NAD+ in liver and skeletal muscle and improved glucose tolerance and hepatic insulin sensitivity in diet- and age-induced diabetic mice, partly via SIRT1 ^[10], and long-term NMN improved insulin sensitivity and energy metabolism across tissues ^[8]. Exercise sits underneath all of it as the non-pharmacological lever, raising NAMPT in human muscle ^[9]. The thread is coherent — but it is a metabolism-and-function thread, not a proof of disease prevention ^[12].

Where the Human Evidence Stops

Raising blood NAD+ is demonstrated; translating it into hard clinical outcomes in humans is not. A 2025 Nature Metabolism review of NAD+ precursor supplementation in human aging concluded that trials have shown limited efficacy on hard clinical endpoints, that age-related NAD+ decline has been consistently observed in only a limited number of human studies, and that tissue-specific NAD+ data remain sparse ^[12]. Much of the strongest anti-aging data comes from rodents and may not extrapolate. A theoretical oncology caution exists because NAD+ supports proliferating cells, so its role in cancer is context-dependent and caution is advised in cancer populations ^[12]. These are the boundaries of what the muscle and metabolic findings currently support — and the reason this digest reports endpoints rather than promises.